Clinical Trials Logo

Chronic Myeloid Leukemia clinical trials

View clinical trials related to Chronic Myeloid Leukemia.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT04360005 Available - Clinical trials for Chronic Myeloid Leukemia in Chronic Phase

Managed Access Programs for ABL001, Asciminib

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to ABL001, asciminib

NCT ID: NCT00854841 Available - Clinical trials for Chronic Myeloid Leukemia

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Start date: n/a
Phase: N/A
Study type: Expanded Access

Research Hypothesis: Treatment with dasatinib 100 mg QD is superior to imatinib 600 mg QD in terms of complete cytogenetic response (CCyR) in chronic phase (CP) Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) subjects who are imatinib failures or who have achieved only a suboptimal response after 3-18 months (12-77 weeks) of therapy with imatinib 400 mg. Primary Objective: The primary objective of this study is to compare the rate of CCyR of dasatinib (100mg QD) to high-dose imatinib (600 mg QD) therapy at 6 months after randomization in CP Ph+ CML subjects who are imatinib failures or who have achieved only a suboptimal response after 3 - 18 months of imatinib monotherapy at 400 mg/day.